Mesenchymal Stromal Cell Therapy in Renal Recipients
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that MSCs in combination with Everolimus facilitate
Tacrolimus withdrawal, reduce fibrosis and decrease the incidence of opportunistic infections
compared to standard tacrolimus dose.